FFF Enterprises: BioSupply Trends Newsletter
Monday, April 16, 2018

Cell-Based and Recombinant Vaccines More Effective in 2017-18 Flu Season

 

In this Issue

•  IVIG/Albumin Supply Index
•  Open Market Pricing
•  New Products from FFF
•  Current Medicare
IVIG / SCIG Rates
•  Resources
•  Subscribe to IG Living and BioSupply Trends Quarterly
 

New data shows cell-based and recombinant vaccines were more effective in the 2017-18 influenza season, according to U.S. Food and Drug Administration commissioner Scott Gottlieb, MD. [ read more ]

Study Finds Mumps Vaccine Protection Wanes Over Time

A recent meta-analysis of six studies of mumps vaccine effectiveness conducted in the U.S. found protection against mumps lasts an average of 27 years after the last dose of the vaccine. The findings suggest that in addition to the recommended two doses of mumps vaccine in childhood, adding a third dose or booster shot at age 18 could help maintain protection. [ read more ]

2018 Budget Act Provision Narrows the Gap for IG Home Infusion Therapy Reimbursement

In February, the Bipartisan Budget Act of 2018 was signed into law by President Trump that includes a provision to more adequately fund immune globulin infusion therapy in the home. [ read more ]

Industry News

 
 

From CSL Behring

The U.S. Food and Drug Administration has approved CSL Behring's Hizentra (immune globulin subcutaneous [human] 20% liquid) for the treatment of chronic inflammatory demyelinating polyneuropathy as a maintenance therapy to prevent relapse of neuromuscular disability and impairment. [ read more ]

From GlaxoSmithKline

GlaxoSmithKline has received breakthrough therapy designation from the U.S. Food and Drug Administration for its meningitis B vaccine Bexsero (meningococcal group B vaccine (rDNA, component, adsorbed]) for the development of the vaccine in the prevention of invasive meningococcal disease caused by serogroup B in children 2 years to 10 years of age.  [ read more ]

From Octapharma

For the second year in a row, Octapharma USA will serve as the exclusive sponsor of "Making the Connection," a national conference for patients with type 3 von Willebrand disease, to be held June 22–25 at the PGA National Resort & Spa in Palm Beach Gardens, Fla. [ read more ]

IVIG & Albumin Supply Index

 
 
 
 

NEW Issue of Biosupply Trends Quarterly!

Current Issue of BSTQ
 
 

In this Issue

•  Banishing Burnout in the Healthcare Setting
•  The Evolution of Medical Aid in Dying
•  Are Drugs Really Overpriced?
•  Healthcare Data: Ensuring Regulatory Compliance
•  Myths and Facts: Cataracts
     
   
     

MyFluVaccine Loyalty Program

Want priority access on flu vaccines
for the 2019-2020 season?

Then take advantage of our NEW inclusive MFV Loyalty Program and enroll for the 2019-2020 season when you go to book your flu vaccine orders for the 2018-2019 season through MyFluVaccine.com

  • Priority access on advance released flu vaccines
  • No minimum purchase
  • Hassle-free
  • Guaranteed booking for the products you need

What's New at FFF

HEPLISAV-B (DYNAVAX TECHNOLOGIES CORP.)

HEPLISAV-B (hepatitis B vaccine [recombinant] adjuvanted) is indicated in adults ages 18 and older for prevention of infection caused by all known subtypes of hepatitis B virus. It is supplied in 0.5 mL single-dose vials.

For more information about HEPLISAV-B, login to biosupply.fffenterprises.com

REBINYN (NOVO NORDISK)

REBINYN (glycoPEGylated) is a recombinant DNA-derived coagulation factor IX concentrate indicated for use in adults and children with hemophilia B for on-demand treatment and control of bleeding episodes and perioperative management of bleeding. It is available as a lyophilized powder in single-use vials of 500, 1,000 and 2,000 IU.

For more information about REBINYN, login to biosupply.fffenterprises.com

These products can be ordered from FFF Enterprise's BioSupply Online Ordering System or by calling
Wow! Customer Care at (800) 843-7477.

Current Medicare IVIG / SCIG Rates

Rates per gram are effective Apr. 1, 2018, through Jun. 30, 2018.

 
Product J Codes ASP + 6%
(before sequester)
ASP + 4.3%*
(after sequester)
IVIG
Carimune NF J1566 $71.06 $69.92
Flebogamma J1572 $70.29 $69.16
Gammagard S/D J1566 $71.06 $69.92
Gammaplex J1557 $78.19 $76.93
Octagam J1568 $82.81 $81.49
Privigen J1459 $79.30 $78.03
SCIG
CUVITRU J1555 $135.25 $133.08
Hizentra J1559 $98.33 $96.75
HyQvia J1575 $138.59 $136.37
IVIG / SCIG
Gammagard Liquid J1569 $79.38 $78.10
Gammaked J1561 $78.29 $77.03
Gamunex-C J1561 $78.29 $77.03

*Reflects 2% sequestration reduction applied to 80% Medicare payment portion as required under Budget Control Act of 2011.

 

Resources

FFF customers may order the following complementary resources to help you with your practice:

•  IG Immune Globulin (Human)
•  Hyperimmune Globulins
•  Anti-Inhibitor, Factor VIIa & IX
•  Factor VIII & von Willebrand Factor
•  Seasonal Influenza Vaccine

Subscribe to IG Living

IG Living is the only magazine for the immune globulin (IG) community for patients who suffer from chronic illness and their caregivers.

Subscribe to BioSupply
Trends Quarterly

BioSupply Trends Quarterly magazine is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace.

Home | About | Advertise | Subscribe | Contact – ©2018 FFF Enterprises, Inc.
This email was sent by: %%Member_Busname%%, %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
Manage preferences: Privacy Policy, Update Profile, Unsubscribe.